Oncternal TherapeuticsONCT
Market Cap: $5.03M
About: Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.
Employees: 27
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
8% more funds holding
Funds holding: 24 [Q1] → 26 (+2) [Q2]
0.75% more ownership
Funds ownership: 15.57% [Q1] → 16.32% (+0.75%) [Q2]
11% less capital invested
Capital invested by funds: $4.15M [Q1] → $3.67M (-$476K) [Q2]
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Northland Capital Markets Carl Byrnes 50% 1-year accuracy 2 / 4 met price target | 18%upside $2 | Market Perform Downgraded | 12 Sept 2024 |
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 116 / 274 met price target | 959%upside $18 | Buy Maintained | 12 Aug 2024 |
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 116 / 274 met price target | 1,018%upside $19 | Buy Reiterated | 16 Jul 2024 |